Epclusa cost can be cheaper

Epclusa is manufactured under the license of Gilead Sciences. It is comparatively cheaper. Sofosbuvir is utilized along with velpatasvir which is a second antiviral drug. This dual effect can be successful in treating both acute and chronic HCV types. Thus, becoming a preferable variant for the first-line treatment.
Epclusa cost in the United States is not negligible and may be estimated at up to $74,760 for a 12-week course of non-insured and co-pay-free therapy. Several programs provide aid to patients in need. To a certain extent, Epclusa is sold in different doses and the physicians prescribe the ideal dose that fits each patient.